New considerations in the design of clinical trials for the treatment of acute leukemia.

about

Future prospects of therapeutic clinical trials in acute myeloid leukemia.Minimal residual disease in acute myeloid leukaemia Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Personalized therapy for acute myeloid leukemia.

P2860

Q30244168-2130A5C2-306A-4412-8B46-1CF8E11693BD Q34179265-4B60F874-D2E4-4BBC-B842-0506F6CBCBDF Q35546759-58BB777A-3DC1-42D9-9947-DC12A38B6EB4 Q37432301-C39BE70A-FE80-4AEA-AEC9-229CAA54F7BB

P2860

New considerations in the design of clinical trials for the treatment of acute leukemia.

Item

http://www.wikidata.org/entity/Q36641721

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

New considerations in the design of clinical trials for the treatment of acute leukemia.

@ast

New considerations in the design of clinical trials for the treatment of acute leukemia.

@en

type

Item

label

New considerations in the design of clinical trials for the treatment of acute leukemia.

@ast

New considerations in the design of clinical trials for the treatment of acute leukemia.

@en

prefLabel

New considerations in the design of clinical trials for the treatment of acute leukemia.

@ast

New considerations in the design of clinical trials for the treatment of acute leukemia.

@en

P1476

New considerations in the design of clinical trials for the treatment of acute leukemia.

@en

P2093

Christopher S Hourigan

http://www.w3.org/2001/XMLSchema#string

Judith E Karp

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.

What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

P304

509-517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/CLI.11.24

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23459118

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

3583301

http://www.w3.org/2001/XMLSchema#string

New considerations in the design of clinical trials for the treatment of acute leukemia.

about

P2860

P2860

New considerations in the design of clinical trials for the treatment of acute leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932